Stroke – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Stroke – Pipeline Review, H2 2016’, provides an overview of the Stroke pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Stroke and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Stroke

The report reviews pipeline therapeutics for Stroke by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Stroke therapeutics and enlists all their major and minor projects

The report assesses Stroke therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Stroke

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Stroke

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Stroke pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AB Science SA

Acticor Biotech

ActiveSite Pharmaceuticals Inc

Addex Therapeutics Ltd

advanceCor GmbH

Affibody AB

Amarantus Bioscience Holdings Inc

Anavex Life Sciences Corp

Angion Biomedica Corp

Antoxis Ltd

APT Therapeutics, Inc.

ArmaGen Inc

Asterias Biotherapeutics, Inc.

AstraZeneca Plc

Athersys Inc

Bayer AG

Bioasis Technologies Inc

Biogen Inc

Boehringer Ingelheim GmbH

Cardax Inc

Cellular Biomedicine Group Inc

CHA Bio & Diostech Co Ltd

ContraVir Pharmaceuticals Inc

CSPC Pharmaceutical Group Limited

D-Pharm Ltd

Daiichi Sankyo Company Ltd

DiaMedica Inc

Diffusion Pharmaceuticals Inc

F. Hoffmann-La Roche Ltd

Fina Biotech

Genervon Biopharmaceuticals LLC

Glialogix Inc

Glucox Biotech AB

Green Cross Corp

Huons Co Ltd

International Stem Cell Corp

Jeil Pharmaceutical Co Ltd

JN-International Medical Corp

Laboratoires Pierre Fabre SA

LegoChem Biosciences Inc

Les Laboratoires Servier SAS

Living Cell Technologies Ltd

Lumosa Therapeutics Co Ltd

M et P Pharma AG

Magnus Life Ltd

Mapreg SAS

Mast Therapeutics Inc

Medestea Research & Production SpA

Mitochon Pharmaceuticals Inc

Mitsubishi Tanabe Pharma Corp

Neuralstem Inc

Neuren Pharmaceuticals Ltd

Neurofx Inc

Neuronax SAS

Neurotec Pharma SL

NeuroVive Pharmaceutical AB

New Haven Pharmaceuticals, Inc.

New World Laboratories Inc

NoNO Inc

NuvOx Pharma LLC

Omeros Corp

Panacea Pharmaceuticals Inc

PharmatrophiX, Inc.

Pharmaxis Ltd

Pharmicell Co Ltd

Phoenix Biotechnology Inc

Phylogica Ltd

PhytoHealth Corp

Pluristem Therapeutics Inc

Primary Peptides, Inc.

Q Therapeutics Inc

QR Pharma Inc

ReCyte Therapeutics Inc

Regenera Pharma Ltd

RegeneRx Biopharmaceuticals Inc

Remedy Pharmaceuticals Inc

ReNeuron Group Plc

SanBio Inc

Saneron CCEL Therapeutics Inc

Shin Poong PharmCo Ltd

Simcere Pharmaceutical Group

Stemedica Cell Technologies Inc

SynZyme Technologies LLC

Targazyme Inc

The International Biotechnology Center (IBC) Generium

TikoMed AB

vasopharm GmbH

Verseon Corp

Vicore Pharma AB

Virogenomics BioDevelopment Inc

WhanIn Pharmaceutical Co Ltd

Zocere Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Stroke Overview 8

Therapeutics Development 9

Stroke - Therapeutics under Development by Companies 11

Stroke - Therapeutics under Investigation by Universities/Institutes 19

Stroke - Pipeline Products Glance 21

Stroke - Products under Development by Companies 24

Stroke - Products under Investigation by Universities/Institutes 33

Stroke - Companies Involved in Therapeutics Development 36

Stroke - Therapeutics Assessment 128

Drug Profiles 145

Stroke - Dormant Projects 466

Stroke - Discontinued Products 481

Stroke - Product Development Milestones 485

Appendix 498

List of Tables

List of Tables

Number of Products under Development for Stroke, H2 2016 29

Number of Products under Development for Stroke – Comparative Analysis, H2 2016 30

Number of Products under Development by Companies, H2 2016 31

Number of Products under Development by Companies, H2 2016 (Contd..1) 32

Number of Products under Development by Companies, H2 2016 (Contd..2) 33

Number of Products under Development by Companies, H2 2016 (Contd..3) 34

Number of Products under Development by Companies, H2 2016 (Contd..4) 35

Number of Products under Development by Companies, H2 2016 (Contd..5) 36

Number of Products under Development by Companies, H2 2016 (Contd..6) 37

Number of Products under Development by Companies, H2 2016 (Contd..7) 38

Number of Products under Investigation by Universities/Institutes, H2 2016 39

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 40

Comparative Analysis by Late Stage Development, H2 2016 41

Comparative Analysis by Clinical Stage Development, H2 2016 42

Comparative Analysis by Early Stage Development, H2 2016 43

Products under Development by Companies, H2 2016 44

Products under Development by Companies, H2 2016 (Contd..1) 45

Products under Development by Companies, H2 2016 (Contd..2) 46

Products under Development by Companies, H2 2016 (Contd..3) 47

Products under Development by Companies, H2 2016 (Contd..4) 48

Products under Development by Companies, H2 2016 (Contd..5) 49

Products under Development by Companies, H2 2016 (Contd..6) 50

Products under Development by Companies, H2 2016 (Contd..7) 51

Products under Development by Companies, H2 2016 (Contd..8) 52

Products under Investigation by Universities/Institutes, H2 2016 53

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 54

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 55

Stroke – Pipeline by AB Science SA, H2 2016 56

Stroke – Pipeline by Acticor Biotech, H2 2016 57

Stroke – Pipeline by ActiveSite Pharmaceuticals Inc, H2 2016 58

Stroke – Pipeline by Addex Therapeutics Ltd, H2 2016 59

Stroke – Pipeline by advanceCor GmbH, H2 2016 60

Stroke – Pipeline by Affibody AB, H2 2016 61

Stroke – Pipeline by Amarantus Bioscience Holdings Inc, H2 2016 62

Stroke – Pipeline by Anavex Life Sciences Corp, H2 2016 63

Stroke – Pipeline by Angion Biomedica Corp, H2 2016 64

Stroke – Pipeline by Antoxis Ltd, H2 2016 65

Stroke – Pipeline by APT Therapeutics, Inc., H2 2016 66

Stroke – Pipeline by ArmaGen Inc, H2 2016 67

Stroke – Pipeline by Asterias Biotherapeutics, Inc., H2 2016 68

Stroke – Pipeline by AstraZeneca Plc, H2 2016 69

Stroke – Pipeline by Athersys Inc, H2 2016 70

Stroke – Pipeline by Bayer AG, H2 2016 71

Stroke – Pipeline by Bioasis Technologies Inc, H2 2016 72

Stroke – Pipeline by Biogen Inc, H2 2016 73

Stroke – Pipeline by Boehringer Ingelheim GmbH, H2 2016 74

Stroke – Pipeline by Cardax Inc, H2 2016 75

Stroke – Pipeline by Cellular Biomedicine Group Inc, H2 2016 76

Stroke – Pipeline by CHA Bio & Diostech Co Ltd, H2 2016 77

Stroke – Pipeline by ContraVir Pharmaceuticals Inc, H2 2016 78

Stroke – Pipeline by CSPC Pharmaceutical Group Limited, H2 2016 79

Stroke – Pipeline by D-Pharm Ltd, H2 2016 80

Stroke – Pipeline by Daiichi Sankyo Company Ltd, H2 2016 81

Stroke – Pipeline by DiaMedica Inc, H2 2016 82

Stroke – Pipeline by Diffusion Pharmaceuticals Inc, H2 2016 83

Stroke – Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 84

Stroke – Pipeline by Fina Biotech, H2 2016 85

Stroke – Pipeline by Genervon Biopharmaceuticals LLC, H2 2016 86

Stroke – Pipeline by Glialogix Inc, H2 2016 87

Stroke – Pipeline by Glucox Biotech AB, H2 2016 88

Stroke – Pipeline by Green Cross Corp, H2 2016 89

Stroke – Pipeline by Huons Co Ltd, H2 2016 90

Stroke – Pipeline by International Stem Cell Corp, H2 2016 91

Stroke – Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016 92

Stroke – Pipeline by JN-International Medical Corp, H2 2016 93

Stroke – Pipeline by Laboratoires Pierre Fabre SA, H2 2016 94

Stroke – Pipeline by LegoChem Biosciences Inc, H2 2016 95

Stroke – Pipeline by Les Laboratoires Servier SAS, H2 2016 96

Stroke – Pipeline by Living Cell Technologies Ltd, H2 2016 97

Stroke – Pipeline by Lumosa Therapeutics Co Ltd, H2 2016 98

Stroke – Pipeline by M et P Pharma AG, H2 2016 99

Stroke – Pipeline by Magnus Life Ltd, H2 2016 100

Stroke – Pipeline by Mapreg SAS, H2 2016 101

Stroke – Pipeline by Mast Therapeutics Inc, H2 2016 102

Stroke – Pipeline by Medestea Research & Production SpA, H2 2016 103

Stroke – Pipeline by Mitochon Pharmaceuticals Inc, H2 2016 104

Stroke – Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2016 105

Stroke – Pipeline by Neuralstem Inc, H2 2016 106

Stroke – Pipeline by Neuren Pharmaceuticals Ltd, H2 2016 107

Stroke – Pipeline by Neurofx Inc, H2 2016 108

Stroke – Pipeline by Neuronax SAS, H2 2016 109

Stroke – Pipeline by Neurotec Pharma SL, H2 2016 110

Stroke – Pipeline by NeuroVive Pharmaceutical AB, H2 2016 111

Stroke – Pipeline by New Haven Pharmaceuticals, Inc., H2 2016 112

Stroke – Pipeline by New World Laboratories Inc, H2 2016 113

Stroke – Pipeline by NoNO Inc, H2 2016 114

Stroke – Pipeline by NuvOx Pharma LLC, H2 2016 115

Stroke – Pipeline by Omeros Corp, H2 2016 116

Stroke – Pipeline by Panacea Pharmaceuticals Inc, H2 2016 117

Stroke – Pipeline by PharmatrophiX, Inc., H2 2016 118

Stroke – Pipeline by Pharmaxis Ltd, H2 2016 119

Stroke – Pipeline by Pharmicell Co Ltd, H2 2016 120

Stroke – Pipeline by Phoenix Biotechnology Inc, H2 2016 121

Stroke – Pipeline by Phylogica Ltd, H2 2016 122

Stroke – Pipeline by PhytoHealth Corp, H2 2016 123

Stroke – Pipeline by Pluristem Therapeutics Inc, H2 2016 124

Stroke – Pipeline by Primary Peptides, Inc., H2 2016 125

Stroke – Pipeline by Q Therapeutics Inc, H2 2016 126

Stroke – Pipeline by QR Pharma Inc, H2 2016 127

Stroke – Pipeline by ReCyte Therapeutics Inc, H2 2016 128

Stroke – Pipeline by Regenera Pharma Ltd, H2 2016 129

Stroke – Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2016 130

Stroke – Pipeline by Remedy Pharmaceuticals Inc, H2 2016 131

Stroke – Pipeline by ReNeuron Group Plc, H2 2016 132

Stroke – Pipeline by SanBio Inc, H2 2016 133

Stroke – Pipeline by Saneron CCEL Therapeutics Inc, H2 2016 134

Stroke – Pipeline by Shin Poong PharmCo Ltd, H2 2016 135

Stroke – Pipeline by Simcere Pharmaceutical Group, H2 2016 136

Stroke – Pipeline by Stemedica Cell Technologies Inc, H2 2016 137

Stroke – Pipeline by SynZyme Technologies LLC, H2 2016 138

Stroke – Pipeline by Targazyme Inc, H2 2016 139

Stroke – Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016 140

Stroke – Pipeline by TikoMed AB, H2 2016 141

Stroke – Pipeline by vasopharm GmbH, H2 2016 142

Stroke – Pipeline by Verseon Corp, H2 2016 143

Stroke – Pipeline by Vicore Pharma AB, H2 2016 144

Stroke – Pipeline by Virogenomics BioDevelopment Inc, H2 2016 145

Stroke – Pipeline by WhanIn Pharmaceutical Co Ltd, H2 2016 146

Stroke – Pipeline by Zocere Inc, H2 2016 147

Assessment by Monotherapy Products, H2 2016 148

Number of Products by Stage and Target, H2 2016 150

Number of Products by Stage and Mechanism of Action, H2 2016 156

Number of Products by Stage and Route of Administration, H2 2016 162

Number of Products by Stage and Molecule Type, H2 2016 164

Stroke – Dormant Projects, H2 2016 486

Stroke – Dormant Projects (Contd..1), H2 2016 487

Stroke – Dormant Projects (Contd..2), H2 2016 488

Stroke – Dormant Projects (Contd..3), H2 2016 489

Stroke – Dormant Projects (Contd..4), H2 2016 490

Stroke – Dormant Projects (Contd..5), H2 2016 491

Stroke – Dormant Projects (Contd..6), H2 2016 492

Stroke – Dormant Projects (Contd..7), H2 2016 493

Stroke – Dormant Projects (Contd..8), H2 2016 494

Stroke – Dormant Projects (Contd..9), H2 2016 495

Stroke – Dormant Projects (Contd..10), H2 2016 496

Stroke – Dormant Projects (Contd..11), H2 2016 497

Stroke – Dormant Projects (Contd..12), H2 2016 498

Stroke – Dormant Projects (Contd..13), H2 2016 499

Stroke – Dormant Projects (Contd..14), H2 2016 500

Stroke – Discontinued Products, H2 2016 501

Stroke – Discontinued Products (Contd..1), H2 2016 502

Stroke – Discontinued Products (Contd..2), H2 2016 503

Stroke – Discontinued Products (Contd..3), H2 2016 504

List of Figures

List of Figures

Number of Products under Development for Stroke, H2 2016 29

Number of Products under Development for Stroke – Comparative Analysis, H2 2016 30

Number of Products under Development by Companies, H2 2016 31

Number of Products under Investigation by Universities/Institutes, H2 2016 39

Comparative Analysis by Late Stage Development, H2 2016 41

Comparative Analysis by Clinical Stage Development, H2 2016 42

Comparative Analysis by Early Stage Products, H2 2016 43

Assessment by Monotherapy Products, H2 2016 148

Number of Products by Top 10 Targets, H2 2016 149

Number of Products by Stage and Top 10 Targets, H2 2016 149

Number of Products by Top 10 Mechanism of Actions, H2 2016 155

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 155

Number of Products by Top 10 Routes of Administration, H2 2016 161

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 161

Number of Products by Top 10 Molecule Types, H2 2016 163

Number of Products by Stage and Top 10 Molecule Types, H2 2016 163

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports